Skip to main content

Fueled by $143M fundraise, Cincy startup doses first patient in new clinical trial

A Cincinnati startup developing treatments for hypertension and other cardio-renal diseases has dosed its first patient in a new clinical trial fueled by a recent $143 million fundraise.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.